Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Mydecine announces filing of patent application for psilocybin-based MYCO-003. Pre-clinical data is showing MYCO-003 to work better than pure psilocybin.
Psyched Wellness is preparing for a clinical sleep study for its proprietary extract, AME-1.
Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.
AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.
Psychedelics media star, Hamilton Morris is joining Compass Pathways as a full-time consultant on psychedelics research.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now